Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September
11 Settembre 2020 - 8:15AM
Oxurion NV Business Update and First Half 2020 Financial Results to
be announced on 17 September
Oxurion NV Business Update and First Half
2020 Financial Results to be announced on 17 September
Oxurion to Host
Conference Call following the H1 Financial
Results
Leuven,
Belgium, 11 September 2020 – 08.15 A.M. CET – Oxurion NV
(Euronext Brussels: OXUR), a biopharmaceutical company developing
next generation standard-of-care therapies, with a focus on
diabetic macular edema (DME), announces that the Company will issue
its Business Update and First Half Financial Results on Thursday,
September 17, 2020 at 5.45 p.m. CET.
Following the announcement, Oxurion’s management
will host a conference call in English on Thursday, September 17 at
6.30 p.m. CET to discuss the Business Update, its Financial Results
and to provide an overview of the progress and potential of the
Company’s emerging DME Franchise.
Oxurion’s First Half 2020 Conference Call & Webcast
Details:
Date: Thursday, September 17, 2020Time: 6.30 p.m. CET / 5.30
p.m. BST
Participant telephone numbers:
Brussels: +32 (0) 2 789 8603Belgium Toll Free:
0800 746 68Standard International Access: +44 (0) 20 3003 2666UK
Toll Free: 0808 109 0700USA Toll Free: 1 866 966
5335
Password: Oxurion
There will be a live listen-only webcast of the event,
accessible from the Oxurion website.
https://www.oxurion.com/news-events
An on-demand version of the event will also be made available
shortly after the event has finished.
END
For further information please
contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56
32wouter.piepers@oxurion.com |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer HallTel:
+44 20 7638 9571oxurion@citigatedewerogerson.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation, standard of
care therapies to better preserve vision in patients with diabetic
macular edema (DME), the leading cause of vision loss in diabetic
patients worldwide.
Oxurion is building a leading global franchise
in the treatment of DME, based on the successful development of its
two novel therapeutics:
- THR-149, a plasma kallikrein inhibitor being
developed as a potential new standard of care for DME patients who
respond sub-optimally to anti-VEGF therapy.
THR-149 has shown positive topline Phase 1 results for the
treatment of DME. The Company is currently conducting a Phase
2 clinical trial evaluating THR-149 with DME-patients who
previously responded sub-optimally to anti-VEGF therapy. THR-149
was developed in conjunction with Bicycle Therapeutics PLC (NASDAQ:
BCYC)
- THR-687, is a pan-RGD integrin inhibitor, that is initially
being developed as a potential new standard of care for all DME
patients. Positive topline results in a Phase 1 clinical study
assessing it as a treatment for DME were announced in January 2020.
THR-687 is expected to enter a Phase 2 clinical trial by
mid-2021.
THR-687 is an optimized compound derived from a broader library
of integrin inhibitors in-licensed from Galapagos NV (Euronext
& NASDAQ: GLPG).
Oxurion is headquartered in Leuven, Belgium, and is listed on
the Euronext Brussels exchange under the symbol OXUR.
More information is available at
www.oxurion.com.
Important information about
forward-looking statementsCertain statements in this press
release may be considered “forward-looking”. Such forward-looking
statements are based on current expectations, and, accordingly,
entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such
forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or any other
reason. Additional information concerning risks and uncertainties
affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is
contained in the Company’s Annual Report. This press release does
not constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mag 2023 a Mag 2024